More News

2026 AGS Meeting Showcases Products Designed for Earlier Intervention

Sessions at the 2026 American Glaucoma Society meeting spotlighted a wave of emerging technologies—from next-generation endoscopic cyclophotoco-agulation and transscleral laser therapy to ultrathin...

Ophthalmologists Report 2.1 Percent Decrease in Q4-2025 Procedure Volume

------ Refractive: -17.3 IOL: +5.0 Glaucoma: +4.2 Retina: -5.7 ----- US ophthalmologists reported that ophthalmic procedures decreased 2.1 percent in Q4-2025 compared with the same quarter in 2024,...

Ophthalmic Company Revenue Down 1.8 Percent in Q4-2025; Seven Firms See Declines

Ophthalmic manufacturer revenue in Q4-2025 totaled $11.8 billion. Revenue decreased 1.8 percent from the same quarter in 2024 and increased 2.5 percent from Q3-2025. The total includes Market Scope...

Premium IOLs Move Mainstream as Revenue Growth Accelerates Globally

The unprecedented premium IOL growth seen over the past five years is expected to continue over the next five years, with premium IOL revenue projected to account for $5.4 billion and 57 percent of...

J&J Vision Gains US FDA Approval for Tecnis PureSee EDOF IOL

Johnson & Johnson Vision announced March 12 that it had gained US FDA approval for the Tecnis PureSee, an extended depth of focus (EDOF) intraocular lens (IOL) for use in cataract surgery. The Jack...

Alcon, Lensar Scrap Acquisition Deal in Face of FTC Opposition

Alcon and Lensar reported March 16 that they were terminating Alcon’s $430 million acquisition of the cataract laser company, in the wake of opposition from the US Federal Trade Commission (FTC). L...

Select US FDA Approvals and Clearances in February 2026

The US FDA’s ophthalmic device division granted clearance to one device using the 510(k) pathway in February 2026, according to the agency’s database. Quantel Medical received clearance for its Int...

PDUFA Dates for Ophthalmic Drug Candidates, March 2026

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

US FDA Rejects Chiesi’s Idebenone for LHON, Asks for More Clinical Data

Chiesi reported March 5 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON)...

US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Citing Trial Failures

Aldeyra Therapeutics reported March 17 that the US FDA had issued a third complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap in dry eye disease. Alde...

Rayner Expands US Headquarters in Memphis Amid Milestone Successes

Rayner reported March 9 that it had opened a new 10 thousand-square-foot facility in Memphis, Tennessee, which will serve as its expanded US headquarters. The UK-based company said the move signifi...

Oertli Launches OS 4 Up Dual-Function Cataract-Vitrectomy System in Europe

Switzerland-based Oertli announced Feb. 23 that its OS 4 Up dual-function cataract/vitrectomy machine is now available in all CE-certified markets. Features include adaptive energy delivery with Ph...

Children’s Hospital Los Angeles Pioneers Aqueous Biopsy Test for Ocular Cancer

Researchers at Children’s Hospital Los Angeles (CHLA) have developed a liquid biopsy test of aqueous humor that they say can significantly improve the diagnosis and clinical management of tumors in...

Science Corp. Leads Latest Fundraising with $230 Million in Series C

Science Corporation led recent ophthalmic fundraising efforts with $230 million in a Series C round to support its Prima implant for dry age-related macular degeneration. Financing announced in the...

Clinical Trial Updates for Ophthalmic Candidates, March 2026

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Root Cause of Myopia Still Eludes Researchers, APAO Congress Reveals

The 2026 APAO congress laid bare the collapse of the old consensus on myopia. It is not yet clear what will take its place. The traditional consensus was that myopia was a lens problem. The very te...

Moderates and Radicals in Myopia Tussle at APAO Congress Over Treatment Goals

Moderates and radicals argued at the 2026 APAO congress over how to respond to the myopia epidemic in Asia. Radicals typically wanted stronger action to stop myopia progression in children than mod...

APAO Congress Looks at Improving the Quality of Cataract Surgery

A two-track cataract surgery market was evident at the APAO congress in Hong Kong. The high-income track typically achieves visual acuity of 20/40 (6/12) or better and offers multifocal lenses to p...

CCOI’s Innovation Meeting Shines Light on Untapped Assets in China

The Collaborative Community on Ophthalmic Innovation (CCOI) held a two-day meeting in Hong Kong prior to the 2026 APAO congress. The CCOI dedicated one day of its meeting to myopia and the other da...

US FDA Will Drop Two-Study Requirement for New Drug Approvals

The US FDA plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, according to a journal article published Feb. 18. Going forward, the agency’s “defaul...

New Law in Kansas Expands ODs’ Scope to Include Laser

Kansas has become the 15th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. House Bill 2223, signed into law by Gov. Laura Kelly on March 12, ...

Emerging Companies Pursuing Ophthalmic Indications, March 2026

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Poll of MDs and ODs, March 2026

March 2026 Ophthalmic News Briefs

STAAR Surgical announced Feb. 17 that the US FDA had approved an expanded age indication for Evo and Evo+ implantable Collamer lenses (ICLs), extending their use from patients 21 to 45 years old to...